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To understand features of human obesity and type 2 diabetes mellitus (T2D) that can be recapitulated in the mouse, we compared
C57BL/6J mice fed a Western-style diet (WD) to weight-matched genetically obese leptin receptor-deﬁcient mice (db/db). All mice
were monitored for changes in body composition, glycemia, and total body mass. To objectively compare diet-induced and genetic
models of obesity, tissue analyses were conducted using mice with similar body mass. We found that adipose tissue inﬂammation
was present in both models of obesity. In addition, distinct alterations in metabolic ﬂexibility were evident between WD-fed mice
and db/db mice. Circulating insulin levels are elevated in each model of obesity, while glucagon was increased only in the db/db
mice. Although both WD-fed and db/db mice exhibited adaptive increases in islet size, the db/db mice also displayed augmented
islet expression of the dediﬀerentiation marker Aldh1a3 and reduced nuclear presence of the transcription factor Nkx6.1. Based
on the collective results put forth herein, we conclude that db/db mice capture key features of human T2D that do not occur in
WD-fed C57BL/6J mice of comparable body mass.

1. Introduction
Obesity is a major risk factor for insulin resistance, metabolic
syndrome, and type 2 diabetes (T2D) [1, 2]. In the human
population, body mass index calculations are often used to
determine metabolic disease risk [3], with stratiﬁcations
ranging from nonobese (18.5–24.9 kg/m2) to overweight
(25–30 kg/m2) to obese (>30 kg/m2). Diﬀerent metabolic disturbances and degrees of risk are often detected within each
subgroup [3, 4]. Consequently, increasing body mass in the
form of excess adiposity is often detrimental to whole body
glucose homeostasis due to a chronic low-grade inﬂammatory condition [5].
On a cellular level, adipocytes play a key role in both fat
storage and production of soluble factors that regulate insulin

sensitivity [6]. In addition, whether excess intracellular lipid
content is stored in adipose tissue or in lean tissues has major
implications for disease risk [7, 8]. Storage of lipid in lean
tissues is detrimental and produces adverse metabolic outcomes [7]. The chronic low-grade inﬂammation associated
with an overabundance of adipose tissue often leads to endocrine alterations and dysfunction of other tissues, such as the
skeletal muscle and liver [5].
During insulin resistance and “prediabetes”, islet β-cells
typically increase in number via proliferation of the existing
cellular population [9–11]. In addition, insulin output is
enhanced prior to diabetes onset to compensate for reduced
action of the hormone in peripheral tissues (e.g., skeletal
muscle and liver). Once a decrease in islet β-cell insulin
secretion and diminutions in the β-cell population or both
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occur, clinical onset of T2D ensues [12]. Clearly, there are
stages of disease progression with earlier metabolic aberrations (e.g., hyperinsulinemia) that ultimately indicate risk of
onset of T2D. Hyperinsulinemia and insulin resistance may
often go undiagnosed but are important “prediabetic” indicators of future disease risk. Progression to overt diabetes
requires a diminution in pancreatic islet β-cell mass, β-cell
function, or both [1, 9, 13].
Pancreatic islet β-cells from human subjects with T2D
display markers of dediﬀerentiation. For example, increased
abundance of Aldh1a3 and reduced nuclear presence of
the transcription factor Nkx6.1 were observed in pancreatic islets from T2D, but not in healthy controls [14].
Nkx6.1 is important for islet β-cell development, suppressing expression of the glucagon gene, and for maintenance
of adult β-cell phenotype [15, 16]. With elevated glucagon
levels being a long known feature of uncontrolled diabetes
[17], it is not surprising that losses in key transcription
factors within islet β-cells could lead to dysregulation of
overall islet hormone production.
During a comparison of C57BL/6J mice fed a high-fat,
sucrose-enriched Western diet (WD) with weight-matched
genetically obese leptin receptor-deﬁcient mice (db/db), several key ﬁndings arose: (1) WD-fed and db/db mice accumulate body weight and fat mass over time at rates higher than
their respective lean control counterparts but similar to each
other. (2) Both WD-fed C57BL/6J mice and db/db mice are
hyperinsulinemic, but only db/db mice are hyperglycemic.
(3) Circulating insulin levels are elevated in both models of
obesity, but glucagon is increased only in the db/db mice.
(4) While both WD-fed C57BL/6J mice and db/db mice
exhibit adaptive increases in islet size, the db/db mice also
display increased islet expression of the dediﬀerentiation
marker Aldh1a3. (5) There is reduced nuclear presence of
the transcription factor Nkx6.1 in db/db mice when compared with mice fed the WD. We conclude that db/db mice
capture key features of human T2D that do not occur in
weight-matched WD-fed C57BL/6J mice.

2. Methods
2.1. Animals and Reagents. Nine-week-old male C57BL/6J
(stock number 00664) and 5-week-old male db/+ and db/db
mice (B6.BKS(D)-Leprdb/J; stock number 00697) were
acquired from the Jackson Laboratories (Bar Harbor, Maine).
These mice were allowed to acclimate to the photoperiod
(12-hour light/12-hour dark) and temperature conditions
(22 ± 1°C) for one week prior to the start of the study.
C57BL/6J mice were randomized into their respective dietary
group assignments based on body weight and blood glucose
measurements such that no signiﬁcant diﬀerences existed
between groups at baseline. At 10 weeks of age, 3 separate
cohorts of mice were started on either control diet (Cat number 98052602; Research Diets Inc., New Brunswick, NJ) or
Western diet (Cat number D12079B; Research Diets Inc.)
for 4, 12, and 20 weeks. The db/db and db/+ mice were
each given access to Lab Diet 5001 ad libitum throughout
the study to represent conditions similar to those used for
colony maintenance at the Jackson laboratory. Blood

Journal of Diabetes Research
glucose was measured weekly using an Accu-Chek Aviva
Plus Glucometer (Roche Diagnostic, Indianapolis, IN).
Weekly measurements of body mass and composition
(fat, lean, and ﬂuid mass) were assessed by NMR using a
Bruker Minispec LF50 Time-Domain NMR system. Upon
completion of the study feeding period, animals were
sacriﬁced by CO2 asphyxiation and decapitation. Whole pancreata were ﬁxed in 10% neutral-buﬀered formalin overnight
prior to sectioning and embedding. Fat depots, liver, and
skeletal muscle were ﬂash frozen in liquid nitrogen and
stored at −80°C. Serum was collected from trunk blood or
cardiac sticks. Pancreatic islets were isolated as described
previously [18]. Relevant animal procedures were approved
by the PBRC and the University of Tennessee Institutional
Animal Care and Use Committees.
2.2. Insulin Tolerance Test, Islet Histology, and Substrate
Oxidation. Mice were fasted for 2 h and were injected intraperitoneally with 0.75 units/kg Humulin R insulin as previously described [19]. Islet histology procedures have been
described [19, 20]. Brieﬂy, the antibodies used were as follows: insulin (Invitrogen; 18-0067; used at 1 : 800), glucagon
(Cell Signaling Technologies; 8233; used at 1 : 400), Aldh1a3
(Novus Biologicals; NBP2-15339; used at 1 : 100), and
Nkx6.1 (F55A12; 1 : 200; [21]). All antibodies were incubated
overnight at 4°C and detected with either Alexa Fluor secondary conjugation (Alexa 488, 594), except for Nkx6.1,
which was detected using a biotin/streptavidin exposure
method. Substrate oxidation was measured in the liver,
and gastrocnemius muscle homogenates were prepared
and used as described previously [22, 23]. Brieﬂy, using
[1-14C] palmitate (100 μM), both complete (14CO2) and
incomplete (14C-acid soluble metabolites (ASMs)) fatty acid
oxidation were assessed ± varying doses of unlabeled pyruvate (0, 0.1, 1, and 10 mM) to assess metabolic ﬂexibility.
2.3. Total RNA Extraction, cDNA Synthesis, and Real-Time
RT-PCR. All procedures have been described previously
[24, 25]. Brieﬂy, total RNA was extracted from mouse islets,
liver, and epididymal fat depots using an RNeasy Mini Kit
(Qiagen). RNA quality and quantity was assessed using a
Nanodrop spectrophotometer (Thermo Scientiﬁc). cDNA
was generated from total RNA using the iScript cDNA
synthesis kit (Bio-Rad). Relative mRNA abundance was
measured by real-time PCR using the iTaq Universal
SYBR Green Supermix (Bio-Rad) on a CFX96 instrument
(Bio-Rad). Transcript levels were normalized with the housekeeping gene Ppia or Rs9. Primer pairs were designed
using the Primer3Plus software.
2.4. Serum ELISA. The following kits were used to measure
serum factors: Mouse/Rat Leptin Quantikine ELISA kit
(Cat number MOB00) from R&D Systems (Minneapolis,
MN), Mouse Insulin ELISA kit (Cat number 10-1247-01)
and Glucagon ELISA kit (Cat number 10-1271-01) from
Mercodia (Uppsala, Sweden), Corticosterone ELISA kit
(Cat number ADI-900-097) from Enzo Life Sciences
(Farmingdale, NY), and the Mouse Adiponectin ELISA kit
(Cat number 80569) from Crystal Chem (Downers Grove,
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IL). Manufacturer’s recommended protocols were used for
all serum measurements.
2.5. Tissue Acyl Glycerol Measurements. Isolated liver (30 mg)
tissue was homogenized in 5% NP-40 solution (300 μL) and
heated twice to 95°C to solubilize all acyl glycerol species.
Samples were centrifuged at maximum speed for 2 minutes,
and supernatant was removed to a clean tube to prevent
contamination with insoluble material. The transferred
samples were diluted 10-fold in water before proceeding
with the detection portion of the assay. Acyl glycerol content
was measured using the Triglyceride Determination kit
(Cat number TR0100) from Sigma Aldrich according to the
manufacturer’s directions.
2.6. Statistics. The data were evaluated with the GraphPad
Prism 6.0 statistical analysis software. Data were analyzed
by either one-way ANOVA using a Tukey post hoc, repeated
measures ANOVA (for longitudinal measures of blood glucose, body weight, and body composition), two-way repeated
measures ANOVA with Bonferroni post hoc test for multiple
comparisons (substrate oxidation), or two-tailed Student’s
t-test. Individual p values are given in the ﬁgure legends.

3. Results
3.1. C57BL/6J Mice Fed a High-Fat, Sucrose-Enriched Diet
Gain Weight but Do Not Develop Hyperglycemia. Over the
course of 20 weeks, male C57BL/6J mice were fed either a
high-fat, high-sucrose Western diet (WD) or sucrosematched low-fat control diet (CD). Blood glucose remained
stable in both groups of mice during this 20-week period
(Figure 1(a)). The study conditions were closely monitored
so that mice fed the WD could be weight matched with db/
db mice. The db/db mice on the C57BL/6 genetic background, which develop obesity secondary to leptin resistance,
display noticeable elevations in blood glucose early in their
lifespan (Figure 1(b)). The db/db mice were compared to lean
littermate heterozygous controls for the leptin receptor
mutation (db/+). The hyperglycemia in db/db mice was
maintained throughout the eight-week study period.
C57BL/6J mice fed the WD gained 22.7 g of total body mass
versus 13.8 g for mice fed the CD (Figures 1(c) and 1(e)).
The db/db mice were fed ad libitum with a low-fat diet
(6% kcal) to mimic conditions commonly used for this
strain. On the low-fat diet, the db/+ animals gained 7.1 g,
while db/db mice increased total body weight by 24 g
(Figures 1(d) and 1(f)). Therefore, although similar accumulation of body mass was observed in C57BL/6J on a Westernstyle diet when compared to db/db mice on a low-fat diet,
there was a noticeable diﬀerence in glycemic control between
these mouse models of obesity.
3.2. db/db Mice Accumulate Adipose Tissue on a Low-Fat Diet
Similar to That Seen with C57BL/6J Mice Fed a Western Diet.
Because the accrual of adipose tissue (fat mass) impacts systemic metabolic parameters [6], we investigated the accumulation of this tissue depot in both diet-induced and genetic
models of obesity. C57BL/6J mice fed the WD displayed consistently elevated fat mass over mice in the CD group
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(Figure 2(a)). We found that db/db mice between the ages
of 6 and 14 weeks of age gained a similar amount of fat mass
(14.5 g) as the C57BL/6J mice on a WD for 20 weeks (13.25 g;
compare Figure 2(c) with Figure 2(d)). However, db/+ mice
did not accumulate signiﬁcant amount of fat mass between
the ages of 6 and 14 weeks (0.56 g; Figures 2(b) and 2(d)),
which we suspect is due to the low amount of fat and sucrose
in this diet. When viewed from a perspective of fat mass as a
percentage of total body mass, the C57BL/6J mice start out
with a relatively low total body fat percentage (~6%) but go
over 30% body fat by week 20 of WD feeding (Figure 2(e)).
Alternatively, the db/db mice start out near 30% total body
fat at 6 weeks of age and increased to over 40% at 14
weeks of age (Figure 2(f)). When lean mass was examined,
both C57BL/6J mice fed a WD and db/db mice display
similar increases in total lean mass, although the db/db
mice had a lower total percentage of whole body lean mass
(Figure 3). Similar ﬁndings were observed when measuring
ﬂuid mass (Figure 3).
3.3. Elevations in Serum Leptin Are Consistent with Increases
in Body Weight and Adiposity in Both Models of Obesity,
While Elevated Corticosterone Is Speciﬁc to db/db Mice.
Leptin is a fat cell-derived hormone that has important roles
in regulating satiety. Serum leptin clearly increases with body
weight in WD-fed mice and is also elevated as the mice get
older (Figure 4(a)). In addition, db/db mice have elevations
in serum leptin over their lean counterparts (Figure 4(b)).
By contrast, corticosterone is relatively stable in the serum
of WD-fed mice (Figure 4(c)) but elevated in db/db mice
(Figure 4(d)). Adiponectin, also derived from adipose tissue,
was not impacted by body weight, adiposity, or age of the
mice (Figures 4(e) and 4(f)).
3.4. There Is Clear Evidence of Inﬂammation in Adipose
Tissue from C57BL/6J Mice Fed a WD and in db/db Mice.
With clear increases in fat mass accumulation between WD
and db/db mice (Figure 2(c) versus Figure 2(d)), we next
measured the expression of genes involved in inﬂammatory
responses using isolated epididymal white adipose tissue
(eWAT). Expression of the Il1α gene, which encodes a proinﬂammatory cytokine, was strongly upregulated in animals
fed WD for 12 weeks relative to mice eating the CD
(Figure 5(a)). By 20 weeks, mice on the control diet were also
displaying elevations in this cytokine (Figure 5(a)); in our
view, this increase in inﬂammation in control mice is most
likely due to aging. Notably, expression of IL-1α was not
signiﬁcantly higher in eWAT from db/db mice relative to
db/+ mice (Figure 5(b)). Nucleotide-binding oligomerization
(NOD) domain-like receptors (NLRs) are in the family of
pattern recognition receptors and have been shown to regulate adipocyte diﬀerentiation in vitro [26]. We observed that
expression of NOD1 is suppressed in mice fed the WD
(Figure 5(c)) and in db/db mice relative to lean controls
(Figure 5(d)). Ccl2, a chemokine that recruits monocytes
and macrophages, was more highly expressed in both WDfed mice (Figure 5(e)) and in db/db mice (Figure 5(f)), relative to their respective lean controls. Moreover, transcript
levels of Cd68, a macrophage marker, were elevated at 12
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Figure 1: Hyperglycemia develops in genetically driven, but not diet-induced obesity. Blood glucose (a) and body weight (c) in male C57BL/
6J mice fed either control or Western diet for 20 weeks. Total weight gain (e) at the end of the 20-week feeding period. Blood glucose (b) and
body weight (d) in male db/+ and db/db mice between 6 and 14 weeks of age. Total weight gain by 14 weeks of age (f). For body weight
measurements (c and d), y-axes are set to the same scale for comparison between study groups. n = 8 per group; means ± SEM;
∗∗∗
p < 0 001 versus control; ∗ p < 0 05 versus control by repeated measures ANOVA. CD: control diet; WD: Western diet.

weeks by WD feeding (Figure 5(g)) and also enhanced in
eWAT from db/db mice (Figure 5(h)).
3.5. There Is Elevated Expression of Glucose 6-Phosphatase,
Acetyl Co-A Carboxylase, and Increased Acyl Glycerols in
the Liver of db/db Mice. Because severe insulin resistance in
the liver is suﬃcient to create whole body glucose intolerance
and elevations in blood glucose [27], we compared the
expression of metabolic enzyme genes expressed in the livers

of db/db mice and mice fed a WD. Livers from db/db mice
displayed much higher expression of the gene encoding glucose 6-phosphatase (Figure 6(a)), while expression of Pck1
was similar between the obese mice (Figure 6(b)). Expression
of acetyl co-A carboxylase 1 was 2.7-fold higher in db/db
mice relative to mice fed a WD (Figure 6(c)), while expression of fatty acid synthase (Figure 6(d)) and stearoyl co-A
desaturase 1 (Figure 6(e)) were similar between the mice.
Consistent with the elevated levels of acetyl co-A carboxylase
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Figure 2: Increased fat mass occurs in both diet-induced and genetically driven forms of obesity. Fat mass (a) and % fat mass (e) in male
C57BL/6J mice fed either control or Western diet for 20 weeks. Total fat mass gain (c) at the end of the 20-week feeding period. Fat mass
(b) and % fat mass (f) in male db/+ and db/db mice between 6 and 14 weeks of age. Total fat mass gain by 14 weeks of age (d). For fat
mass measurements, y-axes are set to the same scale for comparison between study groups. n = 8 per group; means ± SEM; ∗∗∗ p < 0 001
versus control; ∗ p < 0 05 versus control by repeated measures ANOVA. CD: control diet; WD: Western diet.

mRNA, we found that total liver acyl glycerols (mono-, di-,
and tri-glycerols) were 57% higher in db/db mice relative to
mice consuming the WD (Figure 6(f)). Relevant to corticosterone metabolism, the livers of WD-fed mice and db/db
mice showed similar expression of the hsd11b1 gene, which
encodes the enzyme 11beta-hydroxysteroid dehydrogenase
1 (Figure 6(g)). However, expression of the hsd11b2 gene
was markedly reduced in db/db mice relative to mice fed
the WD (Figure 6(h)).

3.6. There Is Reduced Skeletal Muscle Fat Oxidation in WDFed Mice, While Derangements in Both Skeletal Muscle and
Liver Fat Oxidation Are Present in Weight-Matched db/db
Mice. A trait observed during obesity-associated insulin
resistance is the development of metabolic inﬂexibility,
which is deﬁned as the inability to appropriately transition
between diﬀerent fuel sources [28]. To test whether or not
diﬀerences in metabolic ﬂexibility occur at the tissue level
in the diet-induced and genetic models of obesity, we used
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Figure 3: Lean and ﬂuid mass proﬁles in WD-fed and genetically obese db/db mice. Lean mass (a), % lean mass (c), ﬂuid mass (e), and % ﬂuid
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mixed gastrocnemius (MG) skeletal muscle and liver homogenates to measure fatty acid oxidation under conditions
designed to test substrate selection (Figure 7). Compared to
mice fed a control diet, MG from mice fed a Western diet
had no diﬀerence in complete (CO2) palmitate oxidation

(Figure 7(a)); however, MG from these mice did have elevated incomplete fatty acid oxidation rates (i.e., acid soluble
metabolites (ASM); see Figure 7(b)). Alternatively, MG from
db/db mice revealed higher baseline complete (Figure 7(e))
and incomplete (Figure 7(f)) palmitate oxidation than the
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Figure 5: Increased expression of inﬂammatory markers is evident in epididymal adipose tissue from both genetic and diet-induced obesity.
Relative mRNA abundance of the inﬂammatory genes Il1a (a, b), Nod1 (c, d), Ccl2 (e, f), and Cd68 (g, h) in epididymal adipose tissue
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p < 0 01; ∗ p < 0 05; #p < 0 1 by one-way ANOVA with Tukey’s post hoc analysis. (a), (e), and (g) p values versus respective 4-week
dietary group unless denoted by bar. CD: control diet; WD: Western diet; wo: weeks old.
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Figure 7: Derangements in the skeletal muscle and liver fat oxidation occur in db/db mice, while diet-induced obesity only negatively impacts
skeletal muscle fat oxidation. Using [1-14C] palmitate (100 μM), substrate switching was assessed by measuring complete (CO2) and
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lean db/+ controls. Interestingly, the rates of CO2 production
from both db/+ and db/db mice are distinctly lower than
C57BL6/J mice fed either a control or Western diet
(Figure 7(a)). Importantly, palmitate oxidation rates (CO2
and ASM) in MG from both models of obesity had a main
eﬀect for pyruvate concentration indicating substrate switching; however, only genetically obese mice had an interaction
eﬀect (CO2 p = 0 0054; ASM p = 0 0005), indicating db/db
mice exhibit a diﬀerent substrate switching eﬀect than their
lean db/+ counterparts. Moreover, mice fed the control diet
and Western diet (Figure 7(b)), as well as db/+ mice
(Figure 7(f)), all exhibit a decrease in ASM production as
pyruvate concentrations increase. However, db/db mice have
a contrasting rise in incomplete palmitate oxidation under
the same conditions (Figure 7(f)).
In the liver, feeding a Western diet did not alter complete
(Figure 7(c)) or incomplete (Figure 7(d)) palmitate oxidation. By contrast, the liver from db/db mice have slightly
lower basal CO2 production (Figure 7(g)) and clearly demonstrate substantially exaggerated incomplete fat oxidation
(Figure 7(h)). As pyruvate concentrations were increased,
an interaction eﬀect was observed for complete palmitate
oxidation (p = 0 0048) indicating the db/db mice had virtually a complete lack of substrate switching compared to db/
+ controls (Figure 7(g)). Alternatively, no interaction eﬀect
was found concerning ASM production, indicating the
impact of increasing pyruvate levels on incomplete hepatic
fat oxidation was similar between db/+ and db/db mice
(Figure 7(h)). It is notable that db/+ and db/db mice have
lower complete hepatic palmitate oxidation rates, as well as
reduced pyruvate-induced shift in hepatic fatty acid oxidation (CO2 and ASM) than C57BL6/J mice fed either a control
or Western diet (Figure 7).
3.7. Circulating Insulin Levels Are Elevated in Both Models of
Obesity, but Glucagon Is Only Increased in the db/db Mice.
Hyperinsulinemia is present during obesity and is an
independent risk factor for human disease [29, 30]. When
analyzing this parameter in the obese mouse models, we
found 2.5-, 2.6- and 3-fold increases in circulating levels of
insulin at 4, 12, and 20 weeks, respectively, in WD-fed
C57BL/6J mice compared to mice fed the control diet
(Figure 8(a)). By comparison, db/db mice have 15.1-fold
more insulin in circulation than their db/+ counterparts
(Figure 8(b)) at 14 weeks of age. Serum insulin levels strongly
correlated with both total body mass (Figures 8(c) and 8(d))
and fat mass (Figures 8(e) and 8(f)) in both diet-induced and
genetic mouse models of obesity. In contrast to insulin, glucagon levels are unchanged in WD versus CD at 12 and 20
weeks of feeding (Figure 8(g)), while db/db mice displayed
87% more circulating glucagon when compared to the lean
db/+ control mice (Figure 8(h)).
3.8. The Islets of db/db Mice, but Not Western Diet-Fed Mice,
Display Markers of Dediﬀerentiation. Insulin resistance
drives increases in pancreatic islet β-cell mass [9]. Therefore,
we next examined islet architecture between WD-fed mice
and db/db mice. Both models of obesity display increases in
insulin positive area over lean control mice (Figure 9).
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However, islets from db/db mice display clear evidence of
glucagon-positive cells within the core of the islet,
which was not regularly observed in mice fed the WD
(Figure 9(a)). This is consistent with an increase in glucagon
transcripts within islets of db/db mice relative to WD-fed
mice (not shown) and an increase in circulating glucagon in
db/db mice (Figure 8(h)). In addition, we observed less
immunoreactive Nkx6.1 in the nuclei of the db/db islets,
which is consistent with pancreatic islets from humans with
T2D [14]. By contrast, the islets of WD-fed mice retained
strong evidence of nuclear Nkx6.1 expression (Figure 10(a)).
Furthermore, Aldh1a3 expression was markedly elevated in
db/db islets when compared with islets from WD-fed mice
(Figure 10(b)). The increase in transcript is congruent
with the increase in immunoreactive Adh1a3 in islets from
db/db mice, but not in WD-fed C57BL/6J mice (Figure 10(c)).
Taken together, these data are consistent with the premise
that WD-fed mice display features of insulin resistance
(e.g., islet mass expansion), while islets from db/db mice display features of T2D (e.g., elevated glucagon and indicators
of dediﬀerentiation).

4. Discussion
There are many important signs and symptoms that indicate
risk for the eventual development of T2D, including obesity, inﬂammation, insulin resistance, and hyperinsulinemia
[4, 5, 30, 31]. The use of mouse models is important for
understanding the speciﬁc pathways contributing to alterations in tissue function, insulin sensitivity, islet hormone
production, β-cell proliferation, insulin resistance, and overall glucose homeostasis. Therefore, we compared two distinct
models of obesity in mice, the Western diet-fed C57BL/6J
mouse and the db/db mouse on the C57BL/6J genetic background. The results presented in this study have led us to
conclude that in mice with similar body weights, the WDfed C57BL/6J mouse is an excellent model of early features
representing the human prediabetic condition, while the
db/db mouse more closely resembles human T2D.
Elevations in circulating insulin were evident within four
weeks after introduction of the WD to mice (Figure 8(a)).
These data are consistent with hyperinsulinemia in db/db
mice (Figure 8(b)) and observations in the human population [32]. The present ﬁndings are important because hyperinsulinemia is a risk factor for many, if not all, symptoms
used to denote the metabolic syndrome [33–35]. These conditions are readily recapitulated in the WD-fed mouse model
and in the genetically obese db/db mice. In addition, elevated
insulin levels have been suggested to be a causal factor for
obesity [36, 37]. The idea that insulin inﬂuences body weight
and overall adiposity is consistent with the correlations
calculated for circulating insulin with total body mass
(Figures 8(c) and 8(d)) and fat mass (Figures 8(e) and 8(f))
in both WD-fed and genetically obese db/db mice. Moreover,
reducing insulin levels, by using diazoxide to decrease β-cell
insulin output, restricts body weight in rodents by enhancing
metabolic rate and increasing fat oxidation [38].
Human twin studies demonstrate that obesity has a
signiﬁcant genetic component [39]. In addition, there is
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Figure 8: Circulating insulin levels are elevated in both mouse models of obesity, but glucagon is increased only in the db/db mice. Serum
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p < 0 01; ∗ p < 0 05. CD: control diet; WD: Western diet.
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evidence that islet β-cell failure, which is required for progression to T2D, also has a genetic basis [40]. Indeed,
mutations in genes important for adult β-cell phenotype,
such as GLUT2, glucokinase, NeuroD/beta2, HNF1/4,
and Nkx6.1, contribute to deterioration of β-cell function
in human T2D [41]. In our analyses of islets from mice
fed a WD versus islets from db/db mice, we found that
Nkx6.1 is reduced or absent from the nuclei of β-cells in
the islets of db/db mice (Figure 9(a)). Nkx6.1 plays a key
role in negatively controlling expression of the glucagon

gene and therefore maintaining islet β-cells in a mature,
fully diﬀerentiated state [15, 16].
The reduction in nuclear Nkx6.1 that we observe in db/db
islets is also consistent with ﬁndings in pancreatic tissue from
Zucker diabetic fatty rats [42] and in human subjects with
T2D [14]. The increase in glucagon-positive cells we found
in db/db islets (Figure 9(a)) connects changes in the pancreatic islets with the enhanced circulating glucagon in these
mice (Figure 8(h)). Moreover, these data are congruent with
reductions in Nkx6.1 transcripts (see [18]) and nuclear
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protein abundance in the islets of db/db mice (Figure 10(a)).
Importantly, our ﬁndings are relevant to human disease
because hyperglucagonemia is a key feature of the diabetic
state [17, 43, 44]. Insulin resistance in pancreatic alpha
cells may explain the elevations in circulating glucagon
observed in db/db mice. Furthermore, deletion of glucagon
receptors prevents hyperglycemia in obese mice with elevated glucagon [45]. We also see increases in Aldh1a3 transcript and protein in db/db islets (Figures 10(b) and 10(c)),
a recently identiﬁed marker of dysfunctional and/or dediﬀerentiated β-cells [46]. Aldh1a3 is not elevated in the islets
from WD-fed mice (Figures 10(b) and 10(c)) or any of
the lean control mice (not shown), which supports our
interpretation that db/db mice display phenotypes consistent with human T2D while WD-fed C57BL/6 mice may
represent an earlier, nondiabetic stage of obesity and insulin
resistance.
A metabolic signature of insulin-resistant skeletal muscle
is an elevation in incomplete fatty acid oxidation rate, often
measured as accumulation of acid soluble metabolites
[22, 23]. Consistent with this notion, results from the present study show heightened ASM production in both dietinduced and genetic models of obesity. We further note that
complete palmitate oxidation in db/db mice is higher than
db/+ controls in the absence of pyruvate; however, when
moderate (1 mM) or high (10 mM) doses of pyruvate are
present, CO2 production from palmitate is similar between
skeletal muscle from db/+ and db/db mice (Figure 7). At ﬁrst
glance, these ﬁndings are striking as they suggest that
metabolic ﬂexibility at the level of the mitochondria may
actually be better in db/db mice. However, this apparent
improvement seems to come at the expense of an aberrant
response of incomplete fatty acid oxidation (ASMs increase
in presence of higher pyruvate concentrations), suggesting
that greater mitochondrial overload may be occurring in
the db/db mice.
In the liver, feeding a Western diet did not alter complete
(Figure 7(c)) or incomplete (Figure 7(d)) palmitate oxidation. Also, while a main eﬀect for pyruvate concentration
was observed in liver, there was no interaction eﬀect, suggesting that the Western diet had little impact on hepatic fatty
acid oxidative capacity or substrate selection at the level of
the mitochondria. It is, however, worth noting that as pyruvate concentration rises, the liver of the C57BL6/J mice in
the WD-fed group responds by decreasing CO2 liberation
and increasing ASM production, whereas the eﬀect of pyruvate on hepatic fat oxidation in db/+ and db/db mice is much
less pronounced. Elevations in ASMs in response to increasing pyruvate levels could indicate a shift of carbons toward
other metabolic outcomes (e.g., ketogenesis); however, the
hyperinsulinemia induced in the diet-induced (WD fed)
obese mice appears suﬃcient to maintain normoglycemia,
which likely prevents any elevations in circulating ketones.
In adipose tissue, we detected increases in IL-1α
(Figures 5(a) and 5(b)), a key cytokine that signals through
the IL-1R1 and likely contributes to inﬂammatory responses
relevant to insulin resistance. In addition, the expression of
NOD1 was suppressed in both C57BL/6J mice fed the WD
and db/db mice (Figures 5(c) and 5(d)). NOD1 activation

15
blocks adipocyte diﬀerentiation in vitro [26], suggesting that
this pattern recognition receptor may inﬂuence the degree of
adiposity. We now provide in vivo evidence that NOD1
expression is decreased in two diﬀerent mouse models of
obesity, suggesting that reduced NOD1 expression is a component of adipose tissue expansion. By contrast, CCL2, a chemokine that attracts monocytes and macrophages, was
elevated in adipose tissue of both WD-fed mice and db/db
mice (Figures 5(e) and 5(f)). The CCL2 data are congruent
with an increase in the macrophage marker CD68
(Figures 5(g) and 5(h)) and with macrophage accumulation
within adipose tissue of obese rodents and humans [47–49].
We note that db/db mice display elevations in both glucagon and corticosterone (Figures 4 and 8), which may explain
their elevated blood glucose levels relative to mice made
obese by WD feeding (Figure 1). It is possible that db/db mice
have reduced ability to properly regulate their hypothalamicpituitary-adrenal axis due to deﬁciencies in leptin signaling,
thus producing elevations in glucose and corticosterone. This
interpretation is supported by studies from the Friedman
group where speciﬁc deletion of the leptin receptor in hypothalamic brain regions results in elevated plasma levels of
leptin, glucose, insulin, and corticosterone [50]. Thus, physiological leptin signaling appears to be required for proper
corticosterone regulation, which is supported by additional
studies [51]. In addition, we observed much less mRNA
encoding for the 11-β-hydroxysteroid dehydrogenase 2
enzyme (Figure 6(h)). Since this enzyme is responsible for
converting active steroid to inactive steroid, this observation
could help to explain the elevations in circulating corticosterone or prolonged actions of the hormone in db/db mice.
Finally, elevations in corticosterone and glucagon present in
the db/db mice, but not the mice fed a WD, are consistent
with the higher blood glucose observed in db/db mice.
In summary, we conducted a systematic analysis of two
fundamental mouse models of obesity, one representing early
stages of insulin resistance (WD fed) and the other displaying
key features of overt T2D (db/db). With various pharmacologic, dietary, and exercise-based interventions being pursued to prevent or reverse the obese and insulin resistance
state, our novel results are intended to provide a convenient
resource for choosing a mouse model that best mimics the
desired stage of human disease to be studied.
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